navitoclax + Rifampin
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lymphoma, Including Chronic Lymphocytic Leukemia
Conditions
Lymphoma, Including Chronic Lymphocytic Leukemia, Solid Tumors
Trial Timeline
May 1, 2010 → May 1, 2011
NCT ID
NCT01121133About navitoclax + Rifampin
navitoclax + Rifampin is a phase 1 stage product being developed by AbbVie for Lymphoma, Including Chronic Lymphocytic Leukemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01121133. Target conditions include Lymphoma, Including Chronic Lymphocytic Leukemia, Solid Tumors.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01121133 | Phase 1 | Completed |
Competing Products
20 competing products in Lymphoma, Including Chronic Lymphocytic Leukemia